company background image
LOTUSEYE logo

Lotus Eye Hospital and Institute NSEI:LOTUSEYE Stock Report

Last Price

₹59.55

Market Cap

₹1.2b

7D

-0.7%

1Y

-4.9%

Updated

25 Apr, 2024

Data

Company Financials

Lotus Eye Hospital and Institute Limited

NSEI:LOTUSEYE Stock Report

Market Cap: ₹1.2b

Lotus Eye Hospital and Institute Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Lotus Eye Hospital and Institute
Historical stock prices
Current Share Price₹59.55
52 Week High₹111.00
52 Week Low₹48.50
Beta0.30
1 Month Change3.12%
3 Month Change-25.66%
1 Year Change-4.87%
3 Year Change37.05%
5 Year Change205.38%
Change since IPO67.04%

Recent News & Updates

Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) Price Is Out Of Tune With Earnings

Jan 24
Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) Price Is Out Of Tune With Earnings

Recent updates

Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) Price Is Out Of Tune With Earnings

Jan 24
Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) Price Is Out Of Tune With Earnings

Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50

Sep 08
Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50

We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease

Jul 15
We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease

Here's Why Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Has Caught The Eye Of Investors

Apr 07
Here's Why Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Has Caught The Eye Of Investors

We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease

Oct 08
We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease

Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50

Sep 02
Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50

If EPS Growth Is Important To You, Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Presents An Opportunity

Jun 17
If EPS Growth Is Important To You, Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Presents An Opportunity

MD & Whole Time Director Sangeetha Sundaramoorthy Just Bought 2.8% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)

Mar 11
MD & Whole Time Director Sangeetha Sundaramoorthy Just Bought 2.8% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)

Chief Executive Officer K. Ramalingam Just Bought 122% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)

Dec 30
Chief Executive Officer K. Ramalingam Just Bought 122% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)

Insider Buying: The Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) MD & Whole Time Director Just Bought 2.8% More Shares

Nov 20
Insider Buying: The Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) MD & Whole Time Director Just Bought 2.8% More Shares

The Chief Executive Officer of Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE), K. Ramalingam, Just Bought 17% More Shares

Sep 21
The Chief Executive Officer of Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE), K. Ramalingam, Just Bought 17% More Shares

Why Investors Shouldn't Be Surprised By Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) P/E

Aug 27
Why Investors Shouldn't Be Surprised By Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) P/E

Should You Take Comfort From Insider Transactions At Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)?

Aug 03
Should You Take Comfort From Insider Transactions At Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)?

Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) P/E Isn't Throwing Up Surprises

Jul 06
Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) P/E Isn't Throwing Up Surprises

Shareholder Returns

LOTUSEYEIN HealthcareIN Market
7D-0.7%1.3%2.8%
1Y-4.9%64.0%46.6%

Return vs Industry: LOTUSEYE underperformed the Indian Healthcare industry which returned 65.6% over the past year.

Return vs Market: LOTUSEYE underperformed the Indian Market which returned 46.4% over the past year.

Price Volatility

Is LOTUSEYE's price volatile compared to industry and market?
LOTUSEYE volatility
LOTUSEYE Average Weekly Movement11.8%
Healthcare Industry Average Movement6.4%
Market Average Movement6.9%
10% most volatile stocks in IN Market10.1%
10% least volatile stocks in IN Market4.2%

Stable Share Price: LOTUSEYE's share price has been volatile over the past 3 months.

Volatility Over Time: LOTUSEYE's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Indian stocks.

About the Company

FoundedEmployeesCEOWebsite
1997313Kuttapalayam Ramalingamwww.lotuseye.org

Lotus Eye Hospital and Institute Limited, an eye hospital, provides eye care and related services in India. It offers services in the areas of cataract, refractive surgery, retinal disease and diabetic eye care, uvea and ocular inflammation, cornea infections, glaucoma, computer vision syndrome, orbit and oculoplasty, neuro ophthalmology, ocular prosthesis, binocular vision, keratoconus, and zyoptix ultimate, as well as operates an eye bank. In addition, it offers various optical fellowship courses, as well as DNB training services.

Lotus Eye Hospital and Institute Limited Fundamentals Summary

How do Lotus Eye Hospital and Institute's earnings and revenue compare to its market cap?
LOTUSEYE fundamental statistics
Market cap₹1.24b
Earnings (TTM)₹35.38m
Revenue (TTM)₹484.95m

35.0x

P/E Ratio

2.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LOTUSEYE income statement (TTM)
Revenue₹484.95m
Cost of Revenue₹343.46m
Gross Profit₹141.50m
Other Expenses₹106.12m
Earnings₹35.38m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)1.70
Gross Margin29.18%
Net Profit Margin7.30%
Debt/Equity Ratio0.7%

How did LOTUSEYE perform over the long term?

See historical performance and comparison

Dividends

0.8%

Current Dividend Yield

26%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.